[ad_1]
Acer Therapeutics (NASDAQ: ACER) has filed a New Drug Application (NDA) with the FDA for approval of EDSIVO (celiprolol) for the treatment of Ehlers-Danlos Vascular Syndrome (VEDS), a tissue condition connective tissue caused by gene abnormalities encodes collagen. The company has applied for priority review status.
Celiprolol, a drug designed to treat high blood pressure, would be beneficial for VEDS patients by promoting normal collagen synthesis in blood vessels and by moving pressure load away from vessels with high risk of rupture.
Previously: Acer planned an American marketing application for Edsivo for a rare connective tissue disorder; shares in advance of 10% (September 25, 2017)
[ad_2]
Source link
